Emerging Biotechnologies: Challenges Raised for Our Current System of Biosafety Oversight by Gene Drive

Zach N. Adelman
Texas A&M University
Member, RAC
Timeline of laboratory research of gene drive

- 1966: Hickey and Craig meiotic drive
- 1968: Curtis translocation-based gene drive
- 1982: TE transformation of Drosophila
- 1993: TE gene drive in Drosophila
- 1998: TE transformation of mosquitoes
- 2003: Burt HE gene drive
- 2007: MEDEA in Drosophila
- 2011: HEG gene drive mosquitoes
- 2014: Esvelt et al. 2014

Search for naturally occurring or radiation-induced translocations and meiotic drivers
Search for TEs that work in vectors of human pathogens

Gene Drives on the Horizon: Research and Regulation of Biological Gene Drives. AAAS, Volume 3.
**Cut/Repair gene drives**

**Adelman and Tu. Control of Mosquito-Borne Infectious Diseases: Sex and Gene Drive. Trends in Parasitology, March 2016, Vol. 32, No. 3**
A Synthetic Maternal-Effect Selfish Genetic Element Drives Population Replacement in *Drosophila*

Chun-Hong Chen,1 Haixia Huang,1 Catherine M. Ward,1 Jessica T. Su,1 Lorian V. Schaeffer,1 Ming Guo,2 Bruce A. Hay1*  

Concept can be adapted for targeting any maternally deposited transcript vital for embryo survival; Very stable, highly invasive.
Engineered underdominance ($\text{UD}^\text{MEL}$)


More stable than cut/repair strategies, high threshold simplifies containment.
Many diverse molecular genetic strategies to achieve gene drive

Gene drive is not just CRISPR!!!

The (current) tower of risk

- **Exempt**
- **IBC (notification at initiation, eventual approval)**
- **IBC, IRB, (RAC)**
- **IBC, OBA**
- **IBC (approval prior to initiation)**
- **Cloning of potent biological toxins**
- **Generating microorganisms resistant to molecules used for treatment**
- **Gene drive in yeast**
- **Gene drive in plants and rodents**
- **Gene drive in animals (except rodents)**
- **Human Gene Therapy**

**Risk Levels**

- **RISK**
Section III-D-4: Experiments involving whole animals

Gene drives in animals (except rodents) fall into this category and **REQUIRE** IBC approval before beginning any work

Most will fall under BL1 containment: not sufficient for many gene drive types!!!
Risk assessment for laboratory gene drive research

Section V-M. Determination of whether a pathogen has a potential for serious detrimental impact on managed (agricultural, forest, grassland) or natural ecosystems should be made by the Principal Investigator and the Institutional Biosafety Committee, in consultation with scientists knowledgeable of plant diseases, crops, and ecosystems in the geographic area of the research.
Containment practices

- **Physical** (Appendix G, P, Q)
  - Practices
  - Equipment
  - Facilities

- **Biological** (Appendix I)
  - Survival
  - Transmission

No specific guidance for arthropod containment

Modified from: NIH/OBA
Arthropod Containment Guidelines

- Developed by a subcommittee of the American Society of Tropical Medicine and Hygiene in 2003.
- Containment levels 1-4 to mirror handling pathogen-infected arthropods (based on agent BSL)
- Containment ACL-2 designated for genetically-modified arthropods.
- ACG do not mention gene drive, but current interpretations utilize ACL-2 as well.

ACG are not binding and may or may not be utilized by PIs/IBCs
Drosophila, are in fact, arthropods

“Akbari et al. call for stringent regulation of research using *Drosophila melanogaster* on “gene drives,” genetic constructs that at least in a laboratory setting can increase their inheritance above simple Mendelian expectation. The new proposed regulations would include prior committee approval, restrictive laboratory design not readily available in most institutions, and time-consuming biological containment.”

*GSA Public Policy Chair Allan Spradling*

http://genestogenomes.org/gene-drive-more-research-not-more-regulations/
Containment for gene drive research

The PI *suggests* containment conditions and SOPs to the IBC.

The IBC *sets* containment and vets SOPs as part of the approval process.

Containment conditions/work practices are verified by inspections (EHS/BSO) and cannot be changed by the PI without IBC approval (amendment)
Is there a biosafety officer?

NIH guidelines require institutions to have a BSO if they perform any work at BSL3/ABSL3 or above or large scale activities (>10L).

BSO is a permanent member of the IBC and serves as valuable resource in the establishment and review of research protocols including laboratory inspections.
Should RAC have a role in setting containment of gene drive research?
Is there a precedent for gene drive in the world of biocontainment?

Wild-type $\times$ Gene drive

Uninfected $\times$ Infected with vertically-transmitted pathogen
Summary

Gene drive refers to introduced genetic material capable of increasing its frequency in a given population in spite of providing no benefit or even a fitness detriment.

NIH Guidelines currently regulate most, but not all laboratory gene drive experiments, but treat them no differently than other recombinant DNA (BL1).

While IBCs may not have experience with self-propagating gene drives, thinking of these as infectious agents (transmitted vertically) reveals some parallels in lab construction and containment.

In contrast, PIs proposing such experiments may have no experience working under higher containment levels.
Challenges for IBC review of gene drive research

Gene drives present no risk to the health and safety of laboratory workers and thus may not be given as thorough a review as pathogen-based work or human gene therapy.

Some types of gene drive research are currently exempt from the NIH guidelines and thus are not reviewed by the IBC.

No specific guidance on containment for arthropods, biosafety officer may not be present.

NIH guidelines apply NIH-funded entities only.
A updated starting point for risk assessment of laboratory-based transgenic organisms

- Is the introduced trait (or combination of traits) likely to persist or spread through a natural population if introduced?
  - Yes: includes some gene drives but also Mendelian traits that provide a net benefit
  - No: includes some gene drives but also traits that are neutral or confer a disadvantage
IBCs should review all work prior to initiation involving recombinant DNA capable of spreading into a population

*Move these experiments to a new “Section III-D-?”.*

**Section III-E-1.** Experiments Involving the Formation of Recombinant or Synthetic Nucleic Acid Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus

**Section III-D-3.** Experiments Involving the Use of Infectious DNA or RNA Viruses or Defective DNA or RNA Viruses in the Presence of Helper Virus in Tissue Culture Systems

**Section III-E-2.** Experiments Involving Whole Plants (BL1-P)

**Section III-D-5.** Experiments Involving Whole Plants (BL2-4P)